Fig. 2

Percentage of patients who achieve VLFEM at Month 3 and (a) maintained VLFEM status at each of Months 4, 5 or 6, (b) maintained VLFEM status across Months 4, 5 or 6. Abbreviations: CI, confidence interval; GMB, galcanezumab; HFEM, high-frequency episodic migraine; n, number of patients who were categorized as HFEM at baseline with a baseline value and at least one post-baseline value recorded; OR, odds ratio; VLFEM, very low-frequency episodic migraine